Loading organizations...
Ventyx Biosciences has raised $161.0M across 2 funding rounds.
Key people at Ventyx Biosciences.
Ventyx Biosciences has raised $161.0M in total across 2 funding rounds.
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. The company leverages expertise in medicinal chemistry, structural biology, and immunology to discover differentiated small molecule therapeutics. Its pipeline includes programs targeting the NLRP3 inflammasome, S1P1R modulation, and TYK2 inhibition, addressing high unmet medical needs.
Founded in 2018 by Raju Mohan and Chris Krueger, Ventyx Biosciences was established to develop novel, orally available small molecule medicines. CEO Mohan spearheaded its formation, applying advanced medicinal chemistry and immunological understanding to challenging disease pathways, offering alternatives to traditional biologics for chronic conditions.
Ventyx Biosciences targets patients with autoimmune, inflammatory, and neurodegenerative diseases lacking adequate treatment options. The company’s vision is to deliver accessible oral therapies, aspiring to significantly improve the lives of individuals managing these chronic conditions by advancing drug candidates through clinical development.
Ventyx Biosciences has raised $161.0M across 2 funding rounds. Most recently, it raised $51.0M Series B in September 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 20, 2021 | $51M Series B | Surveyor Capital | Cormorant Asset Management, Farallon Capital Management, Janus Henderson Investors, Logos Capital, OrbiMed, Qiming Venture Partners USA, RTW Investments, Third Point, Vivo Capital, Wellington Management | Announced |
| Mar 1, 2021 | $110M Series A | — | Canaan Partners, Nextech Invest, VenBio Partners, Cormorant Asset Management, Farallon Capital Management, Janus Henderson Investors, Logos Capital, OrbiMed, Qiming Venture Partners USA, RTW Investments, Surveyor Capital, Jigar Choksey, Vivo Capital, Wellington Management | Announced |
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for autoimmune, inflammatory, and neurodegenerative diseases. It focuses on high-unmet-need conditions through expertise in medicinal chemistry, structural biology, and immunology, advancing candidates rapidly into clinical trials.[1][2][3] The company's lead programs include NLRP3 inhibitors like VTX2735 (Phase 2 for recurrent pericarditis) and VTX3232 (Phase 2 for neurodegenerative and cardiometabolic diseases), alongside inflammatory bowel disease assets such as tamuzimod (S1P1R modulator) and VTX958 (TYK2 inhibitor), both completing Phase 2 trials.[1][2] Ventyx serves patients with inflammatory and autoimmune disorders, addressing limitations of existing therapies by targeting specific pathways like TYK2 without broader JAK inhibition toxicities.[1][2]
Ventyx Biosciences was founded in 2019 by Raju Mohan, PhD, a serial entrepreneur in immunology-focused pharmaceuticals, based in California.[1][3] Mohan previously founded Akarna Therapeutics, acquired by Allergan for up to $1.2 billion, and other ventures like Oppilan Pharma, Zomagen Biosciences, and Vimalan Biosciences.[1] The company emerged from Mohan's vision to leverage advanced drug discovery for differentiated small molecules in immunology and inflammation. Key leadership includes John (likely John McKew, VP of Drug Discovery with 25+ years advancing 30+ molecules to clinic from roles at Ferring and Exelixis), strengthening early clinical progression.[1]
Ventyx rides the wave of precision immunology therapies, targeting inflammasome pathways like NLRP3 and specific kinases (TYK2, S1P1R) amid rising demand for safer oral alternatives to biologics in autoimmune and neurodegenerative diseases.[1][2] Timing aligns with maturing insights into disease mechanisms—e.g., NLRP3's role in pericarditis and neurodegeneration—fueled by market forces like aging populations, post-pandemic inflammation focus, and biopharma shifts to small molecules for better patient access.[1] As a NASDAQ-listed biotech (VTYX), it influences the ecosystem by validating selective inhibitors, potentially accelerating similar pipeline advancements and attracting investment in inflammation-focused biotechs.[2]
Ventyx's Phase 2 readouts for VTX2735, VTX3232, and prior bowel disease assets position it for potential Phase 3 entry or partnerships by 2026-2027, with NLRP3 and TYK2 programs addressing multi-billion-dollar markets.[1][2] Trends like AI-driven drug design and combo therapies for neurodegeneration will shape its path, amplifying founder-led momentum. Its influence may grow through acquisitions or approvals, evolving from clinical-stage player to key innovator in oral immunology, much like Mohan's prior Akarna success.[1]
Key people at Ventyx Biosciences.
Ventyx Biosciences has raised $161.0M in total across 2 funding rounds.
Ventyx Biosciences's investors include Surveyor Capital, Cormorant Asset Management, Farallon Capital Management, Janus Henderson Investors, Logos Capital, OrbiMed, Qiming Venture Partners USA, RTW Investments, Third Point, Vivo Capital, Wellington Management, Canaan Partners.
